Quinotrierixin inhibited ER stress-induced XBPl mRNA splicing through inhibition of protein synthesis

Bioscience, Biotechnology and Biochemistry

Volumn 75, Issue 2, 2011, Pages 284-288

  Yamamoto, Kohta ^a   Tashiro, Etsu ^a   Imoto, Masaya ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

ER stress; Protein synthesis inhibitor; Quinotrierixin; XBPl

Indexed keywords

DOSE RANGE; ER STRESS; INHIBITORY ACTIVITY; MODE OF ACTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITOR; QUINOTRIERIXIN; UNFOLDED PROTEIN RESPONSE; XBPL;

NUCLEIC ACIDS;

PROTEINS;

ANISOMYCIN; CYCLOHEXIMIDE; DNA BINDING PROTEIN; DRUG DERIVATIVE; MESSENGER RNA; QUINOTRIERIXIN; REGULATORY FACTOR X TRANSCRIPTION FACTORS; RIFABUTIN; TRANSCRIPTION FACTOR;

ARTICLE; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; ENDOPLASMIC RETICULUM; GENETICS; HELA CELL; HUMAN; METABOLISM; PROTEIN SYNTHESIS; PROTEIN UNFOLDING; RNA SPLICING;

ANISOMYCIN; CYCLOHEXIMIDE; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM; HELA CELLS; HUMANS; PROTEIN BIOSYNTHESIS; PROTEIN UNFOLDING; RIFABUTIN; RNA SPLICING; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 79952167191     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.100622     Document Type: Article

References (25)

1. Ellgaard L and Helenius A, Curr. Opin. Cell BioL, 13, 431-437 (2001).
2. Zhou J, Liu CY, Back SH, Clark RL, Peisach D, Xu Z, and Kaufman RJ, Proc. Natl. Acad. Sci. USA, 103, 14343-14348 (2006).
3. Wang XZ, Harding HP, Zhang Y, Jolicoeur EM, Kuroda M, and Ron D, EMBO J., 17, 5708-5717 (1998).
4. Credle JJ, Finer-Moore JS, Papa FR, Stroud RM, and Walter P, Proc. Natl. Acad. Sci. USA, 102, 18773-18784 (2005).
5. Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, Clark SG, and Ron D, Nature, 415, 92-96 (2002).
6. Yoshida H, Matsui T, Yamamoto A, Okada T, and Mori K, Cell, 107, 881-891 (2001).
7. Lee AH, Iwakoshi NN, and Glimcher LH, Mol. Cell. Biol., 23, 7448-7459 (2003).
8. Marciniak SJ and Ron D, Physiol. Rev., 86, 1133-1149 (2006).
9. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgiin C, Glimcher LH, and Hotamisligil GS, Science, 306, 457-461 (2004).
10. Fujimoto T, Onda M, Nagai H, Nagahata T, Ogawa K, and Emi M, Breast Cancer, 10, 301-306 (2003).
11. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, Hada A, Arai M, Wakatsuki T, Matsubara O, Yamamoto N, and Yamamoto M, J. Hepatol, 38, 605-614 (2003).
12. Feldman DE, Chauhan V, and Koong AC, Mol. Cancer Res., 3, 597-605 (2005).
13. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, Mori K, Glimcher LH, Denko NC, Giaccia AJ, Le QT, and Koong AC, Cancer Res., 64, 5943-5947 (2004).
14. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, and Blumberg RS, Cell, 134, 743-756 (2008).
15. Tashiro E, Hironiwa N, Kitagawa M, Futamura Y, Suzuki S, Nishio M, and Imoto M, J. Antibiot. (Tokyo), 60, 547-553 (2007).
16. Futamura Y, Tashiro E, Hironiwa N, Kohno J, Nishio M, Shindo K, and Imoto M, J. Antibiot. (Tokyo), 60, 582-585 (2007).
17. Kawamura T, Tashiro E, Yamamoto K, Shindo K, and Imoto M, J. Antibiot. (Tokyo), 61, 303-311 (2008).
18. Kawamura T, Tashiro E, Shindo K, and Imoto M, J. Antibiot. (Tokyo), 61, 312-317 (2008).
19. Elouil H, Bensellam M, Guiot Y, Vander Mierde D, Pascal SM, Schuit FC, and Jonas JC, Diabetologia, 50, 1442-1452 (2007).
20. Croons V, Martinet W, Herman AG, and De Meyer GR, J. Pharmacol. Exp. Ther., 325, 824-832 (2008).
21. Sugita M, Natori Y, Sueda N, Furihata K, Seto H, and Otake N, J. Antibiot. (Tokyo), 35, 1474-1479 (1982).
22. Kim WG, Song NK, and Yoo ID, J. Antibiot. (Tokyo), 55, 204-207 (2002).
23. Feuerbach D, Waelchli R, Fehr T, and Feyen JH, J. Biol. Chem., 270, 25949-25955 (1995).
24. Azzam ME and Algranati ID, Proc. Natl. Acad. Sci. USA, 70, 3866-3869 (1973).
25. Pestka S, Annu. Rev. Microbiol, 25, 487-562 (1971).